Meeting
2017 ASCO Annual Meeting
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
Authors
Geraldine Helen O'Sullivan Coyne
Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD
Geraldine Helen O'Sullivan Coyne , Shivaani Kummar , Robert S. Meehan , Howard Streicher , Naoko Takebe , Elad Sharon , Barbara A. Conley , Lyndsay Harris , Jerry M. Collins , Nancy Moore , Lamin Juwara , Larry Rubinstein , Mary Flanagan Quinn , Yves Pommier , Mark Cushman , James H. Doroshow , Alice P. Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT01051635
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2558)
DOI
10.1200/JCO.2017.35.15_suppl.2558
Abstract #
2558
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2014 ASCO Annual Meeting
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
First Author: Holly Jane Meany
Poster
2013 ASCO Annual Meeting
A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
First Author: Devalingam Mahalingam